Biocon reports positive results from its Phase 1 comparative PK-PD study

26 Jul 2012 Evaluate

Biocon, Asia’s premier biotechnology company, has reported positive results from a Phase 1 comparative study conducted in Germany of its Biosimilar Insulin Glargine in Type 1 Diabetes Mellitus (T1DM) patients.

This randomized, double-blind, euglycemic clamp study was conducted in T1DM patients to evaluate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of the company’s insulin Glargine against the innovator product (Lantus). The trial met all its primary and secondary endpoints.

The encouraging results indicate that Biocon’s insulin Glargine is equivalent to the innovator product in terms of PK and PD. These robust clinical data along with extensive physicochemical and biological characterization data generated to date between Biocon’s Insulin Glargine and the innovator product will enable Biocon to start its Phase 3 program in the US and EU aimed at demonstrating comparative safety, efficacy and immunogenicity in diabetes mellitus patients.

Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

323.10 4.30 (1.35%)
30-Apr-2025 15:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1830.10
Dr. Reddys Lab 1183.20
Cipla 1550.60
Lupin 2101.05
Zydus Lifesciences 889.75
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...